Xarelto, Pradaxa Difficult To Separate After Positive NICE Final Guidance
This article was originally published in The Pink Sheet Daily
Bayer’s Xarelto has made it into the NHS in England after its NICE recommendation went unchallenged, prompting a head to head battle with Boehringer Ingelheim’s Pradaxa.
You may also be interested in...
U.K. HTA rejects Celgene’s pomalidomide for treating multiple myeloma on cost grounds but waves through Bayer’s rivaroxaban for preventing blood clots in people who have had a heart attack.
NICE has given the thumbs up to Boehringer Ingelheim's Pradaxa in deep vein thrombosis and pulmonary embolism, which means the drug is now set to battle Bayer's Xarelto for market share in this indication.
NICE has cleared a path for Bristol-Myers Squibb’s Eliquis to be included on the British National Health System, but said the data supplied were not robust enough to differentiate the drug from its competition.